Akeso Shares Surge as Cancer Drug Achieves Key Milestone in China Trial

Akeso shares surge as cancer drug achieves key milestone in China trial

Akeso’s Lung Cancer Drug Hits Key Goal In China Study

Akeso Inc. said its closely-watched lung cancer drug has definitively demonstrated for the first time that it could help some patients live longer, potentially boosting its prospects for approval in the US.

Summit partner Akeso says PD-1xVEGF drug hits OS significance in China cancer study

Summit Therapeutics’ partner Akeso reported an incremental piece of good news for the pair’s closely-watched PD-1xVEGF bispecific antibody ivonescimab. In a China-only study called HARMONi-A, ivonescimab plus chemotherapy achieved a statistically significant overall survival benefit ...